Di Maio M, Daniele G, Piccirillo M. Impact on health-related quality of life of the addition of bevacizumab to first-line chemotherapy for ovarian cancer:  . CBN [Internet]. 2013 Oct. 15 [cited 2024 Dec. 4];1(1):33-5. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/254